Infinity Pharmaceuticals, Inc.
INFIQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -15.01% | 12.12% | 20.40% | 66.36% | 33.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.01% | 12.12% | 20.40% | 66.36% | 33.98% |
| Cost of Revenue | -24.54% | -32.92% | -16.09% | 10.38% | 11.42% |
| Gross Profit | 25.31% | 36.28% | 18.09% | -6.91% | -9.93% |
| SG&A Expenses | 7.41% | 61.70% | -14.47% | -8.99% | -0.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.75% | -6.29% | -15.65% | 3.71% | 8.00% |
| Operating Income | 15.79% | 7.25% | 17.06% | -1.22% | -6.82% |
| Income Before Tax | 16.94% | 11.19% | 20.78% | -0.04% | -6.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.94% | 11.19% | 20.78% | -0.04% | -6.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.94% | 11.19% | 20.78% | -0.04% | -6.36% |
| EBIT | 15.79% | 7.25% | 17.06% | -1.22% | -6.82% |
| EBITDA | 15.83% | 7.20% | 17.12% | -1.33% | -6.89% |
| EPS Basic | 17.56% | 11.47% | 21.02% | 0.66% | -5.74% |
| Normalized Basic EPS | 17.62% | 11.47% | 20.93% | 0.66% | -5.79% |
| EPS Diluted | 17.56% | 11.47% | 19.62% | 0.66% | -3.38% |
| Normalized Diluted EPS | 17.62% | 11.47% | 20.93% | 0.66% | -5.79% |
| Average Basic Shares Outstanding | 0.81% | 0.29% | 0.30% | 0.70% | 0.56% |
| Average Diluted Shares Outstanding | 0.81% | 0.29% | 0.30% | 0.70% | 0.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |